相似文献
1
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
Nat Med. 2017 May;23(5):551-555. doi: 10.1038/nm.4308. Epub 2017 Mar 27.
2
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
Clin Cancer Res. 2007 Mar 15;13(6):1810-5. doi: 10.1158/1078-0432.CCR-06-2318.
3
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.
Mod Pathol. 2017 Dec;30(12):1666-1676. doi: 10.1038/modpathol.2017.89. Epub 2017 Aug 4.
4
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
5
Prospects for the use of ipilimumab in treating advanced prostate cancer.
Expert Opin Biol Ther. 2016;16(3):421-32. doi: 10.1517/14712598.2016.1136284. Epub 2016 Jan 25.
6
Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
Clin Cancer Res. 2017 Nov 15;23(22):6812-6822. doi: 10.1158/1078-0432.CCR-17-0807. Epub 2017 Sep 11.
7
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
Oncogene. 2015 Oct;34(43):5411-7. doi: 10.1038/onc.2015.5. Epub 2015 Feb 9.
8
Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Med Oncol. 2017 Sep 1;34(10):170. doi: 10.1007/s12032-017-1029-8.
9
Ipilimumab in prostate cancer.
Expert Opin Biol Ther. 2013 Feb;13(2):303-13. doi: 10.1517/14712598.2012.754421. Epub 2012 Dec 25.
10
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7. doi: 10.1073/pnas.1420370112. Epub 2015 May 11.
引用本文的文献
1
Targeting myeloid cells to improve cancer immune therapy.
Front Immunol. 2025 Jul 31;16:1623436. doi: 10.3389/fimmu.2025.1623436. eCollection 2025.
2
Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming.
Front Pharmacol. 2025 Jul 7;16:1634413. doi: 10.3389/fphar.2025.1634413. eCollection 2025.
3
VISTA functions as a protective immune checkpoint in indirect acute respiratory distress syndrome by modulating systemic and compartmentalized inflammation.
Front Immunol. 2025 Jul 1;16:1618135. doi: 10.3389/fimmu.2025.1618135. eCollection 2025.
4
Unveiling the mechanisms of CEBPD-orchestrated TAM polarization through RGS2/PAR2 pathway and its impact on ICB efficacy in clear cell renal cell carcinoma.
J Immunother Cancer. 2025 Jul 13;13(7):e010898. doi: 10.1136/jitc-2024-010898.
5
Targeting mTORC2 in lung squamous cell carcinoma improves anti-tumor immunity through the PSGL-1-VISTA axis.
Cancer Gene Ther. 2025 Jul 10. doi: 10.1038/s41417-025-00934-4.
6
Immunotherapy in metastatic prostate cancer.
Ther Adv Med Oncol. 2025 Jul 3;17:17588359251347857. doi: 10.1177/17588359251347857. eCollection 2025.
7
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy.
J Immunother Cancer. 2025 Jun 25;13(6):e011929. doi: 10.1136/jitc-2025-011929.
8
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types.
Nat Cancer. 2025 Jun;6(6):967-987. doi: 10.1038/s43018-025-00990-7. Epub 2025 Jun 24.
9
Macrophages in prostate cancer: dual roles in tumor progression and immune evasion.
J Transl Med. 2025 Jun 2;23(1):615. doi: 10.1186/s12967-025-06519-x.
10
The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade.
Front Immunol. 2025 May 9;16:1486799. doi: 10.3389/fimmu.2025.1486799. eCollection 2025.
本文引用的文献
1
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11919-11924. doi: 10.1073/pnas.1611421113. Epub 2016 Oct 3.
2
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.
Nat Commun. 2016 Aug 8;7:12335. doi: 10.1038/ncomms12335.
3
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.
4
Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis.
Cell. 2015 Jul 2;162(1):184-97. doi: 10.1016/j.cell.2015.05.047. Epub 2015 Jun 18.
5
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.
Cell. 2015 Apr 9;161(2):205-14. doi: 10.1016/j.cell.2015.03.030.
6
The future of immune checkpoint therapy.
Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172.
7
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
Oncogene. 2015 Oct;34(43):5411-7. doi: 10.1038/onc.2015.5. Epub 2015 Feb 9.
8
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.
Cancer Immunol Res. 2015 Apr;3(4):326-32. doi: 10.1158/2326-6066.CIR-14-0133. Epub 2014 Dec 19.
9
Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis.
Methods. 2014 Nov;70(1):46-58. doi: 10.1016/j.ymeth.2014.08.016. Epub 2014 Sep 19.
10
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.
Cancer Immunol Res. 2014 Jun;2(6):510-7. doi: 10.1158/2326-6066.CIR-14-0072.
Zotero 插件